---
document_datetime: 2023-09-21 19:30:54
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/lusduna-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: lusduna-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.5201415
conversion_datetime: 2025-12-21 19:39:59.778303
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## LUSDUNA

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary                           |
|----------------------|--------------------------------------------------------------------------------------------------------------|-------------------------------------|------------------------------------------------|----------------------------------|-----------------------------------|
| T/0006               | Transfer of Marketing Authorisation                                                                          | 23/05/2018 product                  | 15/06/2018                                     | SmPC, Labelling and PL           |                                   |
| PSUSA/1751/ 201710   | Periodic Safety Update EU Single assessment - insulin glargine                                               | 17/05/2018                          | n/a                                            |                                  | PRAC Recommendation - maintenance |
| IB/0005              | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a | 12/03/2018                          | n/a                                            |                                  |                                   |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | re-test period/storage period supported by real time data                                                                                     |            |            | authorised                        |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------------------|
| IB/0004            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                | 02/03/2018 | 15/06/2018 | SmPC and PL                       |
| PSUSA/1751/ 201704 | Periodic Safety Update EU Single assessment - insulin glargine                                                                                | 30/11/2017 | n/a        | PRAC Recommendation - maintenance |
| IB/0001            | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 23/06/2017 | n/a        |                                   |

Medicinal product no longer authorised